Inflammation through a psychoneuroimmunological lens

Handbook of Systems and Complexity in Health

Volumn , Issue , 2013, Pages 279-299

  Bennett, Jeanette M ^a,b,c   Gillie, Brandon L ^a   Lindgren, Monica E ^a   Fagundes, Christopher P ^a   Kiecolt Glaser, Janice K ^a,d  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

^d Division of Human Genetics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85016244580     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4998-0_19     Document Type: Chapter

References (229)

1. Ader R, Cohen N. Behaviorally conditioned immunosuppression. Psychosom Med. 1975;37:333-40.
2. Solomon GF. Stress and antibody response in rats. Int Arc Allergy. 1969;35:97-104.
3. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005;5:243-51.
4. Wrona D. Neural-immune interactions: an integrative view of the bidirectional relationship between the brain and immune systems. J Neuroimmunol. 2006;172(1-2):38-58.
5. Maier SF, Watkins LR. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev. 1998;105:83-107.
6. Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun. 2002;16:622-53.
7. Bierhaus A, Wolf J, Andrassy M, Rohleder N, Humpert PM, Petrov D, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci USA. 2003;100(4): 1920-5.
8. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. New Engl J Med. 1997;336(15): 1066-71.
9. Baldwin AS. The NF-kappa B and I kappa B proteins: new discoveries and insights. Ann Rev Immunol. 1996;14:649-83.
10. Chrousos GP, Gold PW. The concepts of stress and stress system disorders. JAMA. 1992;267:1244-52.
11. Sapolsky R, Krey L, McEwen B. Glucocorticoidsensitive hippocampal neurons are involved in terminating the adrenocortical stress response. Proc Natl Acad Sci USA. 1984;81(19): 6174.
12. Da Silva JAP. Sex hormones and glucocorticoids: interactions with the immune system. In: Cutolo M, Masi AT, Bijlsma JWJ, Chikanza IC, Bradlow HL, Castagnetta L, editors. Neuroendocrine immune basis of the rheumatic diseases. New York, NY: New York Acad Sciences; 1999. p. 102-18.
13. Kajantie E, Phillips D. The effects of sex and hormonal status on the physiological response to acute psychosocial stress. Psychoneuroendocrinology. 2006;31(2): 151-78.
14. Taylor SE, Gonzaga GC, Klein LC, Hu P, Greendale GA, Seeman TE. Relation of oxytocin to psychological stress responses and hypothalamic-pituitarydrenocortical axis activity in older women. Psychosom Med. 2006;68(2): 238-45.
15. Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci. 1998;94(6): 557-72.
16. Brattsand R, Linden M. Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies. Aliment Pharmacol Ther. 1996;10:81-90.
17. Sapolsky R, Krey L, McEwen B. Prolonged glucocorticoid exposure reduces hippocampal neuron number: implications for aging. J Neurosci. 1985;5(5): 1222.
18. Webster JC, Cidlowski JA. Downregulation of the glucocorticoid receptor. a mechanism for physiological adaptation to hormones. Ann N Y Acad Sci. 1994;746:216-20.
19. Webster JI, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. Ann Rev Immunol. 2002;20:125-63.
20. Miller G, Cohen S, Ritchey A. Chronic psychological stress and the regulation of pro-inflammatory cytokines: a glucocorticoid-resistance model. Health Psychol. 2002;21(6): 531-41.
21. Sapolsky R, Rivier C, Yamamoto G. Interleukin-1 stimulates the secretion of hypothalmic corticotropin-releasing factor. Science. 1987;238:522-6.
22. Kelley KW, Bluthe RM, Dantzer R, Zhou JH, Shen WH, Johnson RW, et al. Cytokine-induced sickness behavior. Brain Behav Immun. 2003;17 Suppl 1:S112-8.
23. Maier SF, Goehler LE, Fleshner M, Watkins LR. The role of the vagus nerve in cytokine-to-brain communication. Ann N Y Acad Sci. 1998;840(1): 289-300.
24. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9(1): 46-56.
25. Kiecolt-Glaser JK, Gouin J-P, Hantsoo L. Close relationships, inflammation, and health. Neurosci Biobehav Rev. 2010;35(1): 33-8.
26. Mills PJ, Parker B, Dimsdale JE, Sadler GR, Ancoli-Israel S. The relationship between fatigue and qualityoflifeandinflammationduringanthracycline-based chemotherapy in breast cancer. Biol Psychol. 2005;69(1): 85-96.
27. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 2000;51:245-70.
28. Bazzano L, He J, Muntner P, Vupputuri S, Whelton P. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann intrn med. 2003;138(11): 891.
29. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111(12): 1805-12.
30. Bauer J, Hohagen F, Ebert T, Timmer J, Ganter U, Krieger S, et al. Interleukin-6 serum levels in healthy persons correspond to the sleep-wake cycle. Clin Investig. 1994;72(4): 315.
31. Moldofsky H, Lue FA, Eisen J, Keystone E, Gorczynski RM. The relationship of interleukin-1 and immune functions to sleep in humans. Psychosom Med. 1986;48(5): 309-18.
32. Meier-Ewert HK, Ridker PM, Rifai N, Price N, Dinges DF, Mullington JM. Absence of diurnal variation of C-reactive protein concentrations in healthy human subjects. Clin Chem. 2001;47(3): 426-30.
33. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem [Review]. 2004;279(47): 48487-90.
34. Harris T, Ferrucci L, Tracy R, Corti M, Wacholder S, Ettinger WJ, et al. Associations of elevated interleu-kin-6 and C-reactive protein levels with mortality in the elderly. Am J Med. 1999;106:506-12.
35. Eyre H, Kahn R, Robertson RM. Preventing cancer, cardiovascular disease, and diabetes: a common agenda for the American Cancer Society, the American Diabetes Association, and the American Heart Association. Stroke. 2004;35(8): 1999.
36. Hansson G. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med. 2005;352(16): 1685.
37. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917): 868-74.
38. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917): 860-7.
39. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605-21.
40. Marx J. Inflammation and cancer: the link grows stronger. Science. 2004;306:966-8.
41. Duncan B, Schmidt M, Pankow J, Ballantyne C, Couper D, Vigo A, et al. Low-grade systemic inflammation and the development of type 2 diabetes. Diabetes. 2003;52(7): 1799.
42. Hildreth C. Inflammation and diabetes. JAMA. 2008;300(21): 2476.
43. Hotamisligil G, Peraldi P, Budavari A, Ellis R, White M, Spiegelman B. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science. 1996;271(5249): 665.
44. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol. 2001;8(3): 131-6.
45. Bruunsgaard H, Andersen-Ranberg K, Jeune B, Pedersen AN, Skinhoj P, Pedersen BK. A high plasma concentration of TNF-alpha is associated with dementia in centenarians. J Gerontol A Biol Sci Med Sci. 1999;54(7): M357-64.
46. Ferrucci L, Corsi A, Lauretani F, Bandinelli S, Bartali B, Taub DD, et al. The origins of age-related proinflammatory state. Blood. 2005;105(6): 2294-9.
47. Shurin GV, Yurkovetsky ZR, Chatta GS, Tourkova IL, Shurin MR, Lokshin AE. Dynamic alteration of soluble serum biomarkers in healthy aging. Cytokine. 2007;39(2): 123-9.
48. O'Connor MF, Bower JE, Cho HJ, Creswell JD, Dimitrov S, Hamby ME, et al. To assess, to control, to exclude: effects of biobehavioral factors on circulating inflammatory markers. Brain Behav Immun. 2009;23(7): 887-97.
49. Hung J, Knuiman MW, Divitini ML, Davis T, Beilby JP. Prevalence and risk factor correlates of elevated C-reactive protein in an adult Australian population. Am J Cardiol. 2008;101(2): 193-8.
50. Baggio G, Donazzan S, Monti D, Mari D, Martini S, Gabelli C, et al. Lipoprotein(a) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. FASEB J. 1998;12(6): 433-7.
51. Ferrucci L, Harris TB, Guralnik JM, Tracy RP, Corti MC, Cohen HJ, et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc. 1999;47(6): 639-46.
52. Lau DCW, Dhillon B, Yan H, Szmitko PE, Verma S. Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol. 2005;288(5): H2031-41.
53. Ballou SP, Lozanski GB, Hodder S, Rzewnicki DL, Mion LC, Sipe JD, et al. Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons. Age Ageing. 1996;25(3): 224-30.
54. Worns MA, Victor A, Galle PR, Hohler T. Genetic and environmental contributions to plasma C-reactive protein and interleukin-6 levels - a study in twins. Genes Immun. 2006;7(7): 600-5.
55. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350(14): 1387-97.
56. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon III RO, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3): 499-511.
57. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and meta-analyses for the U.S. preventive services task force. Ann Intern Med. 2009;151(7): 483-95.
58. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282(22): 2131-5.
59. Fransson EI, Batty GD, Tabak AG, Brunner EJ, Kumari M, Shipley MJ, et al. Association between change in body composition and change in inflammatory markers: an 11-year follow-up in the Whitehall II Study. J Clin Endocrinol Metab. 2010;95(12): 5370-4.
60. Mohamed-Ali V, Goodrick S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997;82(12): 4196-200.
61. Benson S, Janssen OE, Hahn S, Tan S, Dietz T, Mann K, et al. Obesity, depression, and chronic lowgrade inflammation in women with polycystic ovary syndrome. Brain Behav Immun. 2008;22(2): 177-84.
62. Yudkin JS, Stehouwer CDA, Emeis JJ, Coppack SW. C-reactive protein in wealthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction - a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4):972-8.
63. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleu-kin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001;280(5): E745-51.
64. Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virusdiabetes association. Am J Gastroenterol. 2003;98(12): 2751-6.
65. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, Garcia-Porrua C, Sanchez-Andrade A, Martin J, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24(1): 83-6.
66. Krogh-Madsen R, Plomgaard P, Moller K, Mittendorfer B, Pedersen BK. Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab. 2006;291(1): E108-14.
67. Nicklas BJ, Ambrosius W, Messier SP, Miller GD, Penninx BW, Loeser RF, et al. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am J Clin Nutr. 2004;79(4): 544-51.
68. Dandona P, Weinstock R, Thusu K, Abdel-Rahman E, Aljada A, Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J Clin Endocrinol Metab. 1998;83(8): 2907-10.
69. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289(14): 1799-804.
70. Bruun JM, Stallknecht B, Helge JW, Richelsen B. Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol. 2007;157(4): 465-71.
71. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Rimm EB. Leisure-time physical activity and reducedplasmalevelsofobesity-relatedinflammatory markers. Obes Res. 2003;11(9): 1055-64.
72. Hamer M, Steptoe A. Prospective study of physical fitness, adiposity, and inflammatory markers in healthy middle-aged men and women. Am J Clin Nutr. 2009;89(1): 85-9.
73. Jacobson DL, Gange SJ, Rose NR, Graham NMH. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol. 1997;84(3): 223-43.
74. Czlonkowska A, Ciesielska A, Gromadzka G, Kurkowska-Jastrzebska I. Estrogen and cytokines production - the possible cause of gender differences in neurological diseases. Curr Pharm Des. 2005;11(8): 1017-30.
75. Rosen JL, Tran HT, Lackey A, Viselli SM. Sexrelated immune changes in young mice. Immunol Invest. 1999;28(4): 247-56.
76. Grimaldi CM, Cleary J, Dagtas AS, Moussai D, Diamond B. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest. 2002;109(12): 1625-33.
77. Tanriverdi F, Silveira LFG, MacColl GS, Bouloux PMG. The hypothalamic-pituitary-gonadal axis: immune function and autoimmunity. J Endocrinol [Review]. 2003;176(3): 293-304.
78. Khera A, McGuire DK, Murphy SA, Stanek HG, Das SR, Vongpatanasin W, et al. Race and gender differences in C-reactive protein levels. J Am Coll Cardiol. 2005;46(3): 464-9.
79. Nazmi A, Oliveira IO, Victora CG. Correlates of C-reactive protein levels in young adults: a population-based cohort study of 3827 subjects in Brazil. Braz J Med Biol Res. 2008;41(5): 357-67.
80. Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB, et al. Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J. 2006;152(3): 593-8.
81. Jilma B, Dirnberger E, Loscher I, Rumplmayr A, Hildebrandt J, Eichler HG, et al. Menstrual cycleassociated changes in blood levels of interleukin-6, alpha 1 acid glycoprotein, and C-reactive protein. J Lab Clin Med. 1997;130(1): 69-75.
82. Muzzio ML, Berg G, Zago V, Basilio F, Sanguinetti S, Lopez G, et al. Circulating small dense LDL, endothelial injuring factors and fibronectin in healthy postmenopausal women. Clin Chim Acta. 2007;381(2): 157-63.
83. Eilertsen AL, Hoibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas. 2005;52(2): 111-8.
84. Lacut K, Oger E, Le Gal G, Blouch MT, Abgrall JF, Kerlan V, et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost. 2003;90(1): 124-31.
85. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies onmarkersofinflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause. 2006;13(4): 643-50.
86. Vitale C, Cornoldi A, Gebara O, Silvestri A, Wajngarten M, Cerquetani E, et al. Interleukin-6 and flow-mediated dilatation as markers of increased vascular inflammation in women receiving hormone therapy. Menopause. 2005;12(5): 552-8.
87. van Rooijen M, Hansson LO, Frostegard J, Silveira A, Hamsten A, Bremme K. Treatment with combined oral contraceptives induces a rise in serum C-reactive protein in the absence of a general inflammatory response. J Thromb Haemost. 2006;4(1): 77-82.
88. Kiecolt-Glaser JK, Loving TJ, Stowell JR, Malarkey WB, Lemeshow S, Dickinson SL, et al. Hostile marital interactions, proinflammatory cytokine production, and wound healing. Arch Gen Psychiatry. 2005;62:1377-84.
89. Sadeghi M, Daniel V, Naujokat C, Weimer R, Opelz G. Strikingly higher interleukin (IL)-1 alpha, IL-1 beta and soluble interleukin-1 receptor antagonist (sIL-1RA) but similar IL-2, sIL-2R, IL-3, IL-4, IL-6, sIL-6R, IL-10, tumour necrosis factor (TNF)-alpha, transforming growth factor (TGF)-beta(2) and interferon IFN-gamma urine levels in healthy females compared to healthy males: protection against urinary tract injury? Clin Exp Immunol. 2005;142(2):312-7.
90. Souter I, Janzen C, Martinez-Maza O, Breen EC, Stanczyk F, Chaudhuri G, et al. Serum levels of soluble vascular cell adhesion molecule-1 are decreased in women receiving oral contraceptives compared with normally menstruating women: implications in atherosclerosis. Fertil Steril. 2005;83(5): 1480-8.
91. Willis C, Morris JM, Danis V, Gallery EDM. Cytokine production by peripheral blood monocytes during the normal human ovulatory menstrual cycle. Hum Reprod. 2003;18(6): 1173-8.
92. Abrahamsen B, Stilgren LS, Rettmer E, Bonnevie-Nielsen V, Beck-Nielsen H. Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1 beta and IL-6. Calcif Tissue Int. 2003;72(1): 18-23.
93. O'Brien SM, Fitzgerald P, Scully P, Landers A, Scott LV, Dinan TG. Impact of gender and menstrual cycle phase on plasma cytokine concentrations. Neuroimmunomodulation. 2007;14(2): 84-90.
94. Yasui T, Uemura H, Yamada M, Matsuzaki T, Tsuchiya N, Noguchi M, et al. Associations of interleukin-6 with interleukin-1 beta interleukin-8 and macrophage inflammatory protein-1 beta in midlife women. Cytokine. 2008;41(3): 302-6.
95. Kluft C, Leuven JA, Helmerhorst FM, Krans HM. Pro-inflammatory effects of oestrogens during use of oral contraceptives and hormone replacement treatment. Vascul Pharmacol. 2002;39:149-54.
96. Giraldo E, Hinchado MD, Garcia JJ, Ortega E. Influence of gender and oral contraceptives intake on innate and inflammatory response. Role of neuroendocrine factors. Mol Cell Biochem. 2008;313(1-2):147-53.
97. Straub RH, Hense HW, Andus T, Scholmerich J, Riegger GAJ, Schunkert H. Hormone replacement therapy and interrelation between serum interleu-kin-6 and body mass index in postmenopausal women: a population-based study. J Clin Endocrinol Metab. 2000;85(3): 1340-4.
98. Abrahamsen B, Bonnevie-Nielsen V, Ebbesen EN, Gram J, Beck-Nielsen H. Cytokines and bone loss in a 5-year longitudinal study - hormone replacement therapy suppresses serum soluble interleukin-6 receptor and increases interleukin-1-receptor antagonist: the Danish Osteoporosis Prevention Study. J Bone Miner Res. 2000;15(8): 1545-54.
99. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55(7): 580-92.
100. Massie MJ. Prevalence of depression in patients with cancer. J Natl Cancer Inst Monogr. 2004;32:57-71.
101. Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, et al. Increased plasmaconcentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord. 1995;34(4): 301-9.
102. Bremmer MA, Beekman AT, Deeg DJ, Penninx BW, Dik MG, Hack CE, et al. Inflammatory markers in late-life depression: results from a population-based study. J Affect Disord. 2008;106(3): 249-55.
103. Lesperance F, Frasure-Smith N, Theroux P, Irwin M. The association between major depression and levels of soluble intercellular adhesion molecule 1, inter-leukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiat. 2004;161(2): 271-7.
104. Suarez EC, Krishnan RR, Lewis JG. The relation of severity of depressive symptoms to monocyte-associated proinflammatory cytokines and chemokines in apparently healthy men. Psychosom Med. 2003;65(3): 362-8.
105. Ford DE, Erlinger TP. Depression and C-reactive protein in US adults: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med. 2004;164(9): 1010-4.
106. Glaser R, Robles TF, Sheridan J, Malarkey WB, Kiecolt-Glaser JK. Mild depressive symptoms are associated with amplified and prolonged inflammatory responses after influenza virus vaccination in older adults. Arch Gen Psychiatry. 2003;60(10): 1009-14.
107. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychoph. 2002;5(4): 401-12.
108. Pace TWW, Mletzko TC, Alagbe O, Musselman DL, Nemeroff CB, Miller AH, et al. Increased stressinduced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry. 2006;163(9): 1630-2.
109. Miller GE, Rohleder N, Stetler C, Kirschbaum C. Clinical depression and regulation of the inflammatory response during acute stress. Psychosom Med. 2005;67(5): 679-87.
110. Miller GE, Freedland KE, Carney RM. Depressive symptoms and the regulation of proinflammatory cytokine expression in patients with coronary heart disease's. J Psychosom Res. 2005;59(4): 231-6.
111. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry. 2001;58(5): 445-52.
112. Bryclon L, Harrison NA, Walker C, Steptoe A, Critchley HD. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatry. 2008;63(11): 1022-9.
113. Anisman H, Merali Z, Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog Neurobiol. 2008;85(1): 1-74.
114. Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol. 2006;21(4): 227-31.
115. Muller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, et al. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry. 2006;11(7): 680-4.
116. Carroll JE, Low CA, Prather AA, Cohen S, Fury JM, Ross DC, et al. Negative affective responses to a speech task predict changes in interleukin (IL)-6. Brain Behav Immun. 2011;25(2): 232-8.
117. Maes M, Song C, Lin A, De Jongh R, Van Gastel A, Kenis G, et al. The effects of psychological stress on humans: increased production of pro-inflammatory cytokines and a Th1-like response in stress-induced anxiety. Cytokine. 1998;10(4): 313-8.
118. Pitsavos C, Panagiotakos DB, Papageorgiou C, Tsetsekou E, Soldatos C, Stefanadis C. Anxiety in relation to inflammation and coagulation markers, among healthy adults: the ATTICA study. Atherosclerosis. 2006;185(2): 320-6.
119. Kiecolt-Glaser JK, Heffner KL, Glaser R, Malarkey WB, Porter K, Atkinson C, et al. How stress and anxiety can alter immediate and late phase skin test responses in allergic rhinitis. Psychoneuroendocrinology. 2009;34(5): 670-80.
120. Montinaro V, Iaffaldano GP, Granata S, Porcelli P, Todarello O, Schena FP, et al. Emotional symptoms, quality of life and cytokine profile in hemodialysis patients. Clin Nephrol. 2010;73(1): 36-43.
121. Adler N, Boyce T, Chesney M, Cohen S, Folkman S, Kahn R, et al. Socioeconomic status and health. Am Psychol. 1994;49:15-24.
122. Adler N, Rehkopf D. US disparities in health: descriptions, causes, and mechanisms. Annu Rev Public Health. 2008;29(1): 235.
123. Haan M, Kaplan GA, Camacho T. Poverty and health - prospective evidence from the Alameda County Study. Am J Epidemiol. 1987;125(6): 989-98.
124. Bucher HC, Ragland DR. Socioeconomic indicators and mortality from coronary heart-disease and cancer - a 22-year follow-up of middle-aged men. Am J Public Health. 1995;85(9): 1231-6.
125. Lantz PM, House JS, Lepkowski JM, Williams DR, Mero RP, Chen JM. Socioeconomic factors, health behaviors, and mortality - results from a nationally representative prospective study of US adults. JAMA. 1998;279(21): 1703-8.
126. Singh GK, Siahpush M. Widening socioeconomic inequalities in US life expectancy, 1980-2000. Int J Epidemiol. 2006;35(4): 969-79.
127. Marmot MG, Smith GD, Stansfeld S, Patel C, North F, Head J, et al. Health Inequalities among British Civil-Servants - the Whitehall-Ii Study. Lancet. 1991;337(8754): 1387-93.
128. Marmot MG, Shipley MJ, Rose G. Inequalities in death - specific explanations of a general pattern. Lancet. 1984;1(8384): 1003-6.
129. Koster A, Bosma H, Penninx BWJH, Newman AB, Harris TB, van Eijk JTM, et al. Association of inflammatory markers with socioeconomic status. J Gerontol A Biol Sci Med Sci. 2006;61(3): 284-90.
130. Jousilahti P, Salomaa V, Rasi V, Vahtera E, Palosuo T. Association of markers of systemic inflammation, C reactive protein, serum amyloid A, and fibrinogen, with socioeconomic status. J Epidemiol Community Health. 2003;57(9): 730-3.
131. Gruenewald TL, Cohen S, Matthews KA, Tracy R, Seeman TE. Association of socioeconomic status with inflammation markers in black and white men and women in the Coronary Artery Risk Development in Young Adults (CARDIA) study. Soc Sci Med. 2009;69(3): 451-9.
132. Steptoe A, Owen N, Kunz-Ebrecht S, Mohamed-Ali V. Inflammatory cytokines, socioeconomic status, and acute stress responsivity. Brain Behav Immun. 2002;16(6): 774-84.
133. Ranjit N, Diez-Roux AV, Shea S, Cushman M, Ni H, Seeman T. Socioeconomic position, race/ethnicity, and inflammation in the multi-ethnic study of atherosclerosis. Circulation. 2007;116(21): 2383-90.
134. Friedman EM, Herd P. Income, education, and inflammation: differential associations in a national probability sample (The MIDUS Study). Psychosom Med. 2010;72(3): 290-300.
135. Brydon L, Edwards S, Mohamed-Ali V, Steptoe A. Socioeconomic status and stress-induced increases in interleukin-6. Brain Behav Immun. 2004;18(3): 281-90.
136. Owen N, Poulton T, Hay FC, Mohamed-Ali V, Steptoe A. Socioeconomic status, C-reactive protein, immune factors, and responses to acute mental stress. Brain Behav Immun. 2003;17(4): 286-95.
137. Uchino BN. Understanding the links between social support and physical health: a life-span perspective with emphasis on the separability of perceived and received support. Perspect Psychol Sci. 2009;4(3): 236-55.
138. Friedman EM, Hayney MS, Love GD, Urry HL, Rosenkranz MA, Davidson RJ, et al. Social relationships, sleep quality, and interleukin-6 in aging women. Proc Natl Acad Sci USA. 2005;102(51): 18757-62.
139. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer. 2005;104(2): 305-13.
140. Lutgendorf SK, Anderson B, Sorosky JI, Buller RE, Lubaroff DM. Interleukin-6 and use of social support in gynecologic cancer patients. Int J Behav Med. 2000;7(2): 127-42.
141. Lillard L, Waite L. 'Til death do us part: Marital disruption and mortality. Am J Sociol. 1995;100(5): 1131-56.
142. Sbarra DA. Marriage protects men from clinically meaningful elevations in C-reactive protein: results from the national social life, health, and aging project (NSHAP). Psychosom Med. 2009;71(8): 828-35.
143. Kiecolt-Glaser JK, Newton TL. Marriage and health: his and hers. Psychol Bull. 2001;127(4): 472-503.
144. Kiecolt-Glaser JK, Glaser R, Cacioppo JT, Malarkey WB. Marital stress: immunologic, neuroendocrine, and autonomic correlates. Ann N Y Acad Sci. 1998;840:656-63.
145. Graham JE, Glaser R, Loving TJ, Malarkey WB, Stowell JR, Kiecolt-Glaser JK. Cognitive word use during marital conflict and increases in proinflammatory cytokines. Health Psychol. 2009;28(5): 621-30.
146. Shen BJ, Farrell KA, Penedo FJ, Schneiderman N, Orth-Gomer K. Waist circumference moderates the association between marital stress and C-reactive protein in middle-aged healthy women. Ann Behav Med. 2010;40(3): 258-64.
147. Kardys I, Knetsch A, Bleumink G, Deckers J, Hofman A, Stricker B, et al. C-reactive protein and risk of heart failure. The Rotterdam Study. Am Heart J. 2006;152(3): 514-20.
148. US Department of Health and Human Services. The Health Consequences of Smoking: A Report of the Surgeon General. 2004; Atlanta, GA: Centers for Disease Control and Prevention.
149. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. Br Med J. 2004;328(7455): 1519.
150. Cross CE, Traber M, Eiserich J, van der Vliet A. Micronutrient antioxidants and smoking. Br Med Bull. 1999;55(3): 691-704.
151. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-Reactiveproteinandothermarkersofinflammation in the prediction of cardiovascular disease in women. New Engl J Med. 2000;342(12): 836-43.
152. Tracy RP, Psaty BM, Macy E, Bovill EG, Cushman M, Cornell ES, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997;17(10): 2167-76.
153. Das I. Raised C-reactive protein levels in serum from smokers. Clin Chim Acta. 1985;153(1): 9-13.
154. Wannamethee SG, Lowe GDO, Shaper AG, Rumley A, Lennon L, Whincup PH. Associations between cigarette smoking, pipe/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J. 2005;26(17): 1765-73.
155. Bermudez EA, Rifai N, Buring JE, Manson JE, Ridker PM. Relation between markers of systemic vascular inflammation and smoking in women. Am J Cardiol. 2002;89(9): 1117-9.
156. Bo S, Gentile L, Ciccone G, Baldi C, Benini L, Dusio F, et al. The metabolic syndrome and high C-reactive protein: prevalence and differences by sex in a southern-European population-based cohort. Diabetes Metab Res Rev. 2005;21(6): 515-24.
157. Haddy N, Sass C, Maumus S, Marie B, Droesch S, Siest G, et al. Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur J Hum Genet. 2005;13(1): 109-17.
158. Bazzano LA, He J, Muntner P, Vupputuri S, Whelton PK. Relationship between cigarette smoking and novel risk factors for cardiovascular disease in the United States. Ann Intern Med. 2003;138(11): 891-7.
159. Mendall MA, Strachan DP, Butland BK, Ballam L, Morris J, Sweetnam PM, et al. C-reactive protein: relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men. Eur Heart J. 2000;21(19): 1584-90.
160. Frohlich M, Sund M, Lowel H, Imhof A, Hoffmeister A, Koenig W. Independent association of various smoking characteristics with markers of systemic inflammation in men - results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). Eur Heart J. 2003;24(14): 1365-72.
161. Lowe GDO, Editorial B. Why do smokers have higher plasma fibrinogen levels than non-smokers? Clin Sci. 2001;101(2):209-10.
162. Hastie CE, Haw S, Pell JP. Impact of smoking cessation and lifetime exposure on C-reactive protein. Nicotine Tob Res. 2008;10(4): 637-42.
163. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GDO. Associations of blood rheology and interleu-kin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol. 1999;104(2): 246-57.
164. Wannamethee SG, Whincup PH, Rumley A, Lowe GDO. Inter-relationships of interleukin-6, cardiovascular risk factors and the metabolic syndrome among older men. J Thromb Haemost. 2007;5(8): 1637-43.
165. Helmersson J, Larsson A, Vessby B, Basu S. Active smoking and a history of smoking are associated with enhanced prostaglandin F-2 alpha, interleukin-6 and F-2-isoprostane formation in elderly men. Atherosclerosis. 2005;181(1): 201-7.
166. Petrescu F, Voican SC, Siolosi I. Tumor necrosis factor-alpha serum levels in healthy smokers and nonsmokers. Int J Chron Obstruct Pulmon Dis. 2010;5:217-22.
167. Berrahmoune H, Lamont JV, Herbeth B, FitzGerald P, Visvikis-Siest S. Biological determinants of and reference values for plasma interleukin-8, monocyte chemoattractant protein-1, epidermal growth factor, and vascular endothelial growth factor: results from the STANISLAS cohort. Clinl Chem. 2006;52(3): 504-10.
168. Pedersen BK, Febbraio MA. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev. 2008;88(4): 1379-406.
169. Febbraio MA, Pedersen BK. Muscle-derived inter-leukin-6: mechanisms for activation and possible biological roles. FASEB J. 2002;16(11): 1335-47. Official Publication of the Federation of American Societies for Experimental Biology.
170. Fischer CP. Interleukin-6 in acute exercise and training: what is the biological relevance? Exerc Immunol Rev. 2006;12:6-33.
171. Nielsen AR, Pedersen BK. The biological roles of exercise-induced cytokines: IL-6, IL-8, and IL-15. Appl Physiol Nutr Metab. 2007;32(5): 833-9.
172. Pedersen BK, Steensberg A, Fischer C, Keller C, Keller P, Plomgaard P, et al. Searching for the exercise factor: is IL-6 a candidate? J Muscle Res Cell Motil. 2003;24(2):113-9.
173. Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK. Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J. 2003;17(3): 884-6.
174. Borodulin K, Laatikainen T, Salomaa V, Jousilahti P. Associations of leisure time physical activity, selfrated physical fitness, and estimated aerobic fitness with serum C-reactive protein among 3,803 adults. Atherosclerosis. 2006;185(2): 381-7.
175. Ford ES. Does exercise reduce inflammation? Physical activity and c-reactive protein among U.S. adults. Epidemiology. 2002;13:561-8.
176. Jankord R, Jemiolo B. Influence of physical activity on serum IL-6 and IL-10 levels in healthy older men. Med Sci Sports Exerc. 2004;36(6): 960-4.
177. Goldhammer E, Tanchilevitch A, Maor I, Beniamini Y, Rosenschein U, Sagiv M. Exercise training modulates cytokines activity in coronary heart disease patients. Int J Cardiol. 2005;100(1): 93-9.
178. Okita K, Nishijima H, Murakami T, Nagai T, Morita N, Yonezawa K, et al. Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thromb Vasc Biol. 2004;24(10):1868-73.
179. Troseid M, Lappegard KT, Claudi T, Damas JK, Morkrid L, Brendberg R, et al. Exercise reduces plasma levels of the chemokines MCP-1 and IL-8 in subjects with the metabolic syndrome. Eur Heart J. 2004;25(4): 349-55.
180. Pullen PR, Nagamia SH, Mehta PK, Thompson WR, Benardot D, Hammoud R, et al. Effects of yoga on inflammation and exercise capacity in patients with chronic heart failure. J Card Fail. 2008;14(5): 407-13.
181. Kiecolt-Glaser JK, Christian L, Preston H, Houts CR, Malarkey WB, Emery CF, et al. Stress, inflammation, and yoga practice. Psychosom Med. 2010;72(2): 113-21.
182. Knoops KT, de Groot LC, Kromhout D, Perrin AE, Moreiras-Varela O, Menotti A, et al. Mediterranean diet, lifestyle factors, and 10-year mortality in elderly European men and women: the HALE project. JAMA. 2004;292(12): 1433-9.
183. Schulze MB, Hoffmann K, Manson JE, Willett WC, Meigs JB, Weikert C, et al. Dietary pattern, inflammation, and incidence of type 2 diabetes in women. Am J Clin Nutr. 2005;82(3): 675-84. quiz 714-5.
184. Nettleton JA, Steffen LM, Mayer-Davis EJ, Jenny NS, Jiang R, Herrington DM, et al. Dietary patterns are associated with biochemical markers of inflammation and endothelial activation in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Clin Nutr. 2006;83(6): 1369-79.
185. Lopez-Garcia E, Schulze MB, Fung TT, Meigs JB, Rifai N, Manson JE, et al. Major dietary patterns are related to plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr. 2004;80(4): 1029-35.
186. Calder PC, Albers R, Antoine JM, Blum S, Bourdet-Sicard R, Ferns GA, et al. Inflammatory disease processes and interactions with nutrition. Br J Nutr. 2009;101 Suppl 1:S1-45.
187. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceri-demia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002;106(10): 1211-8.
188. Bowen PE, Borthakur G. Postprandial lipid oxidation and cardiovascular disease risk. Curr Atheroscler Rep. 2004;6(6): 477-84.
189. Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol. 2002;39(7): 1145-50.
190. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002;106(16): 2067-72.
191. O'Keefe JH, Gheewala NM, O'Keefe JO. Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol. 2008;51(3): 249-55.
192. Giugliano D, Ceriello A, Esposito K. The effects of diet on inflammation: emphasis on the metabolic syndrome. J Am Coll Cardiol. 2006;48(4): 677-85.
193. Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83(6 Suppl):1505S-19.
194. Mozaffarian D, Pischon T, Hankinson SE, Rifai N, Joshipura K, Willett WC, et al. Dietary intake of trans fatty acids and systemic inflammation in women. Am J Clin Nutr. 2004;79(4): 606-12.
195. Pischon T, Hankinson SE, Hotamisligil GS, Rifai N, Willett WC, Rimm EB. Habitual dietary intake of n-3 and n-6 fatty acids in relation to inflammatory markers among US men and women. Circulation. 2003;108(2): 155-60.
196. Novak TE, Babcock TA, Jho DH, Helton WS, Espat NJ. NF-kappa B inhibition by omega-3 fatty acids modulates LPS-stimulated macrophage TNF-alpha transcription. Am J Physiol Lung Cell Mol Physiol. 2003;284(1): L84-9.
197. Zhao Y, Joshi-Barve S, Barve S, Chen LH. Eicosapentaenoic acid prevents LPS-induced TNF-alpha expression by preventing NF-kappaB activation. J Am Coll Nutr. 2004;23(1): 71-8.
198. Dew MA, Hoch CC, Buysse DJ, Monk TH, Begley AE, Houck PR, et al. Healthy older adults' sleep predicts all-cause mortality at 4 to 19 years of follow-up. Psychosom Med. 2003;65(1): 63-73.
199. Tamakoshi A, Ohno Y. Self-reported sleep duration as a predictor of all-cause mortality: results from the JACC study, Japan. Sleep. 2004;27(1): 51-4.
200. Ferrie JE, Shipley MJ, Cappuccio FP, Brunner E, Miller MA, Kumari M, et al. A prospective study of change in sleep duration: associations with mortality in the Whitehall II cohort. Sleep. 2007;30(12): 1659-66.
201. Spiegel K, Knutson K, Leproult R, Tasali E, Van Cauter E. Sleep loss: a novel risk factor for insulin resistance and Type 2 diabetes. J Appl Physiol. 2005;99(5): 2008-19.
202. Benca RM, Obermeyer WH, Thisted RA, Gillin JC. Sleep and psychiatric-disorders - a metaanalysis. Arch Gen Psychiatry. 1992;49(8): 651-68.
203. Redwine L, Hauger RL, Gillin JC, Irwin M. Effects of sleep and sleep deprivation on interleukin-6, growth hormone, cortisol, and melatonin levels in humans. J Clin Endocrinol Metab. 2000;85:3597-603.
204. Motivala SJ, Irwin MR. Sleep and immunity - cytokine pathways linking sleep and health outcomes. Curr Dir Psychol Sci. 2007;16(1): 21-5.
205. Mullington J, Korth C, Hermann DM, Orth A, Galanos C, Holsboer F, et al. Dose-dependent effects of endotoxin on human sleep. Am J Physiol Regul Integr Comp Physiol. 2000;278(4): R947-55.
206. Haack M, Schuld A, Kraus T, Pollmacher T. Effects of sleep on endotoxin-induced host responses in healthy men. Psychosom Med. 2001;63(4): 568-78.
207. Spath-Schwalbe E, Hansen K, Schmidt F, Schrezenmeier H, Marshall L, Burger K, et al. Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab. 1998;83(5): 1573-9.
208. Shoham S, Davenne D, Cady AB, Dinarello CA, Krueger JM. Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep. Am J Physiol. 1987;253(1 Pt 2):R142-9.
209. Irwin MR, Wang M, Ribeiro D, Cho HJ, Olmstead R, Breen EC, et al. Sleep loss activates cellular inflammatory signaling. Biol Psychiatry. 2008;64(6): 538-40.
210. Irwin MR, Wang M, Campomayor CO, Collado-Hidalgo A, Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med. 2006;166(16): 1756-62.
211. Shearer WT, Reuben JM, Mullington JM, Price NJ, Lee BN, Smith EO, et al. Soluble TNF-alpha receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight. J Allergy Clin Immunol. 2001;107(1): 165-70.
212. Meier-Ewert HK, Ridker PM, Rifai N, Regan MM, Price NJ, Dinges DF, et al. Effect of sleep loss on C-reactive protein, an inflammatory marker of cardiovascular risk. J Am Coll Cardiol. 2004;43(4): 678-83.
213. Alberti A, Sarchielli P, Gallinella E, Floridi A, Mazzotta G, Gallai V. Plasma cytokine levels in patients with obstructive sleep apnea syndrome: a preliminary study. J Sleep Res. 2003;12(4): 305-11.
214. Arter JL, Chi DS, Girish M, Fitzgerald SM, Guha B, Krishnaswamy G. Obstructive sleep apnea, inflammation, and cardiopulmonary disease. Front Biosci. 2004;9:2892-900.
215. Epel ES, Blackburn EH, Lin J, Dhabhar FS, Adler NE, Morrow JD, et al. Accelerated telomere shortening in response to life stress. Proc Natl Acad Sci USA. 2004;101(49): 17312-5.
216. Simon NM, Smoller JW, McNamara KL, Maser RS, Zalta AK, Pollack MH, et al. Telomere shortening and mood disorders: preliminary support for a chronic stress model of accelerated aging. Biol Psychiatry. 2006;60(5): 432-5.
217. Epel ES, Lin J, Dhabhar FS, Wolkowitz OM, Puterman E, Karan L, et al. Dynamics of telomerase activity in response to acute psychological stress. Brain Behav Immun. 2010;24(4): 531-9.
218. Damjanovic AK, Yang Y, Glaser R, Kiecolt-Glaser JK, Nguyen H, Laskowski B, et al. Accelerated telomere erosion is associated with a declining immune function of caregivers of Alzheimer's disease patients. J Immunol. 2007;179(6): 4249-54.
219. Parks C, Miller D, McCanlies E, Cawthon R, Andrew M, DeRoo L, et al. Telomere length, current perceived stress, and urinary stress hormones in women. Cancer Epidemiol Biomarkers Prev. 2009;18(2): 551.
220. Blackburn EH. Switching and signaling at the telomere. Cell. 2001;106(6): 661-73.
221. Blackburn EH. Telomere states and cell fates. Nature. 2000;408:53-6.
222. Kiecolt-Glaser JK, Glaser R. Psychological stress, telomeres, and telomerase. Brain Behav Immun. 2010;24(4): 529-30.
223. Aviv A. Telomeres and human aging: facts and fibs. Sci Aging Knowledge Environ. 2004;51:pe43.
224. Lung FW, Chen NC, Shu BC. Genetic pathway of major depressive disorder in shortening telomeric length. Psychiatr Genet. 2007;17(3): 195-9.
225. Tyrka AR, Price LH, Kao HT, Porton B, Marsella SA, Carpenter LL. Childhood maltreatment and telomere shortening: preliminary support for an effect of early stress on cellular aging. Biol Psychiatry. 2010;67(6): 531-4.
226. Kiecolt-Glaser JK, Gouin JP, Weng N, Malarkey WB, Beversdorf DQ, Glaser R. Childhood adversity heightens the impact of later-life caregiving stress on telomere length and inflammation. Psychosom Med. 2011;73(1): 16.
227. Valdes AM, Andrew T, Gardner JP, Kimura M, Oelsner E, Cherkas LF, et al. Obesity, cigarette smoking, and telomere length in women. Lancet. 2005;366(9486): 662-4.
228. Epel ES. Telomeres in a life-span perspective: a new "Psychobiomarker"? Curr Dir Psychol Sci. 2009;18(1):6-10.
229. Cherkas LF, Hunkin JL, Kato BS, Richards JB, Gardner JP, Surdulescu GL, et al. The association between physical activity in leisure time and leukocyte telomere length. Arch Intern Med. 2008;168(2): 154-8.